| Karrie Calzo, MA CCC-SLP | |
|
120 Parkside Dr, Ashland, OH 44805-1545 | |
| (419) 774-2507 | |
| Not Available |
| Full Name | Karrie Calzo |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 120 Parkside Dr, Ashland, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457776759 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SP 8035 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karrie Calzo, MA CCC-SLP 120 Parkside Dr, Ashland, OH 44805-1545 Ph: () - | Karrie Calzo, MA CCC-SLP 120 Parkside Dr, Ashland, OH 44805-1545 Ph: (419) 774-2507 |
News Archive
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that John Muir Physician Network Clinical Research Center has agreed to participate in the United States Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for the Company's flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product.
In a recently published review article in the journal Drug Discovery Today, scientists have described the utility of human-based microphysiological systems MPSs in understanding the pathophysiology of SARS-CoV-2 infection and developing effective therapeutic interventions. Moreover, they have described the establishment of a global working group to synchronize recent developments around MPSs and COVID-19 research.
A team of scientists from Japan has identified the approved anti-material drug, mefloquine, as a potential candidate to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Specifically, mefloquine has been shown to prevent the entry of SARS-CoV-2 into host cells and reduce the viral load in vitro.
In a promising development for diabetes treatment, researchers have developed a network of nanoscale particles that can be injected into the body and release insulin when blood-sugar levels rise, maintaining normal blood sugar levels for more than a week in animal-based laboratory tests.
› Verified 9 days ago
Mrs. Christine J. Signoracci, M.A. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1256 Center St, Ashland, OH 44805 Phone: 419-289-0470 | |
Mrs. Lesley Ann Wickham, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 221 E Walnut St, Ashland, OH 44805 Phone: 419-606-9435 | |
Melissa Humphrey, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 622 Center St, Ashland, OH 44805 Phone: 419-289-3523 | |
Mrs. Terri Lynn Drushell, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 825 Smith Rd, Ashland, OH 44805 Phone: 419-289-7969 | |
Shannon Lange, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1256 Center St, Ashland, OH 44805 Phone: 419-289-0470 | |
Kimberly Hovey, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1256 Center St, Ashland, OH 44805 Phone: 909-915-5563 |